International Edition
Latest News
Health

Top Korean Stock Picks: Dongkook Pharm, Samsung SDI, and Bionia

Dongkuk Pharmaceutical achieved its largest quarterly revenue in history during the second quarter, according to MTNW advisor Bae Jun-ho. Market analysts note the company is undergoing a re-rating from a traditional pharmaceutical firm to a K-beauty growth stock,…

Top Korean Stock Picks: Dongkook Pharm, Samsung SDI, and Bionia

Dongkuk Pharmaceutical achieved its largest quarterly revenue in history during the second quarter, according to MTNW advisor Bae Jun-ho. Market analysts note the company is undergoing a re-rating from a traditional pharmaceutical firm to a K-beauty growth stock, with cosmetic exports projected to surpass 1,000억 원 this year.

Dongkuk Pharmaceutical Leads K-Beauty Growth Stocks

Dongkuk Pharmaceutical reported record-breaking second-quarter sales figures, signaling a shift in market perception. According to MTNW advisor Bae Jun-ho, the company’s traditional pharmaceutical portfolio is now complemented by expanding cosmetic sales. Financial projections indicate that annual cosmetic exports will exceed 1,000억 원. Market participants have established a target price of 25,500 won with a stop-loss threshold set at 19,500 won.

Samsung SDI Secures Major Battery and ESS Contracts

Samsung SDI secured a new battery project order from Mercedes-Benz alongside a long-term supply agreement worth over 2조 won with an American energy storage system enterprise, according to MTNW advisor Seo Jae-hong. The industrial momentum highlights initiatives including cylindrical battery projects tailored for hybrid electric vehicles. Observers have outlined a target price of 700,000 won and a stop-loss mark of 518,000 won for the stock.

Bionia Advances Hair Loss Treatments and Clinical Research

Bionia is progressing with follow-up studies for its CosmeRNA product following the publication of human application test results for stress-related hair loss in an American academic journal, according to MTNW advisor Lim Kwang-bin. Global investment banks have characterized the treatment as a potential next-generation blockbuster. Market advisors have set a target price of 10,000 won alongside a stop-loss boundary of 7,900 won.

Market Summary of Featured Investment Targets

  • Dongkuk Pharmaceutical: Second-quarter sales hit a record high; cosmetic exports projected above 1,000억 원; target price 25,500 won, stop-loss 19,500 won.
  • Samsung SDI: Mercedes-Benz battery project win and US ESS contract; target price 700,000 won, stop-loss 518,000 won.
  • Bionia: Stress-related hair loss study published in a US journal; target price 10,000 won, stop-loss 7,900 won.
About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”